Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Healthcare Reform Brings Little Short-term Benefit For China’s Pharmaceutical Companies

This article was originally published in PharmAsia News

Executive Summary

China's highly anticipated healthcare reform plan rollout (PharmAsia News, Apr. 8, 2009) has raised questions, especially about the details of essential drug pricing. The new plan modifies the previous price ceiling for retail drugs to the current government-recommended prices, providing more objectivity. For instance, the rural-to-city expense ratio now stands at 3:7, which may improve to 50:50 after the reform. However, some drug makers worry that essential drugs may be fixed at a much lower rate, eroding profits for quality products. Analysts believe the pharma industry will see little profit improvement in the next three years due to thorny drug-related issues such as essential drug catalog and dissociating hospital income and drug sales. (Click here for more - Chinese language)

You may also be interested in...

China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion

SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts